VTGN
VistaGen Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$22.82M
P/E Ratio
—
EPS
$-1.90
Beta
0.33
52W High
$5.14
52W Low
$0.43
50-Day MA
$0.58
200-Day MA
$2.35
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About VistaGen Therapeutics Inc
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential to treat anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 789,000 |
| Gross Profit (TTM) | 789,000 |
| EBITDA | $-69.72M |
| Operating Margin | -6451.00% |
| Return on Equity | -101.60% |
| Return on Assets | -55.50% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $1.28 |
| Price-to-Book | 0.44 |
| Price-to-Sales (TTM) | 28.92 |
| EV/Revenue | 134.38 |
| EV/EBITDA | -0.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 29.50% |
| Shares Outstanding | $39.62M |
| Float | $33.78M |
| % Insiders | 0.27% |
| % Institutions | 38.25% |
Historical Volatility
HV 10-Day
64.38%
HV 20-Day
62.58%
HV 30-Day
55.88%
HV 60-Day
68.59%
HV Rank
—
Volatility is currently expanding
Data last updated: 4/14/2026